https://www.selleckchem.com/pr....oducts/tenapanor.htm
Malignant Pleural Mesothelioma (MPM) remains a major oncological challenge with limited therapeutic options. HSV1716 is a replication restricted oncolytic herpes simplex virus with anti-tumor effects in multiple cell lines including MPM. Intrapleural treatment appeals because MPM is typically multifocal but confined to the pleura, and distant metastases are uncommon. We assessed the safety and possible efficacy of intrapleural HSV1716 for inoperable MPM. Patients with MPM received 1 × 10 iu HSV1716 injected via an indwelling intrapleu
Like
Comment
Share
